MX2022007626A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2022007626A
MX2022007626A MX2022007626A MX2022007626A MX2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A
Authority
MX
Mexico
Prior art keywords
combinations
disease
treating
compounds
condition
Prior art date
Application number
MX2022007626A
Other languages
English (en)
Spanish (es)
Inventor
Brant Clayton Boren
Kevin Duane Bunker
Fernando Donate
Peter Qinhua Huang
Jiali Li
Hooman Izadi
Ahmed Abdi Samatar
Joseph Robert Pinchman
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022007626A publication Critical patent/MX2022007626A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
MX2022007626A 2019-12-20 2020-12-16 Combinaciones. MX2022007626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962952039P 2019-12-20 2019-12-20
PCT/US2020/065409 WO2021127044A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
MX2022007626A true MX2022007626A (es) 2022-09-23

Family

ID=76478095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007626A MX2022007626A (es) 2019-12-20 2020-12-16 Combinaciones.

Country Status (12)

Country Link
US (1) US20230008362A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069235A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631348B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119442A (cg-RX-API-DMAC7.html)
CN (1) CN115427042A (cg-RX-API-DMAC7.html)
AU (1) AU2020407070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012281A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165472A1 (cg-RX-API-DMAC7.html)
IL (1) IL294080A (cg-RX-API-DMAC7.html)
MX (1) MX2022007626A (cg-RX-API-DMAC7.html)
TW (1) TW202132299A (cg-RX-API-DMAC7.html)
WO (1) WO2021127044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183776A1 (en) 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Also Published As

Publication number Publication date
IL294080A (en) 2022-08-01
EP4069235A4 (en) 2024-01-10
WO2021127044A1 (en) 2021-06-24
EP4069235A1 (en) 2022-10-12
CN115427042A (zh) 2022-12-02
KR20220119442A (ko) 2022-08-29
AU2020407070A1 (en) 2022-07-14
JP7631348B2 (ja) 2025-02-18
US20230008362A1 (en) 2023-01-12
CA3165472A1 (en) 2021-06-24
BR112022012281A2 (pt) 2022-08-30
JP2023508328A (ja) 2023-03-02
TW202132299A (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PT3883579T (pt) Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
MX2022007628A (es) Combinaciones.
CR20220251A (es) Nuevos derivados de metilquinazolinona
EA202193015A1 (ru) Ингибиторы cdk
MX2020011868A (es) Inhibidores de los receptores erbb.
MX389672B (es) Inhibidores de ssao de aminopirimidina
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2022007623A (es) Combinaciones.
JOP20210050B1 (ar) معدلات تعبير pnpla3
MX381994B (es) Inhibidor de janus quinasa.
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
CO2024009571A2 (es) Inhibidores de parp1
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA202191519A1 (ru) Модуляторы trex1
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
JOP20200291A1 (ar) معدلات التعبير عن apol1
BR112022012278A2 (pt) Combinações
BR112022012281A2 (pt) Combinações
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
CL2022001511A1 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer